Prices delayed by at least 15 minutes | Print


Novo-Nordisk A/S (NVO)

ADR
Sell: $127.45|Buy: $128.95|Change: 1.36 (-1.05%)

Open 

$128.33


Previous close 

$129.41


Trade high 

$128.62


Volume 

3,941,235


Year high 

$138.28


Year low 

$75.56


Dividend yield 

1.06%


Market capitalisation 

$571.36 bn


P/E ratio 

47.97


ISIN 

US6701002056


This share can be held in a Dealing accountISALifetime ISAJISASIPP

Share price

Dividends

PreviousLatest
Record date21/08/202325/03/2024
Ex-dividend date18/08/202322/03/2024
Payment date29/08/202302/04/2024
Amount$0.44178065$0.92985

Performance 27/03/2024

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
Novo-Nordisk A/S- 1.05
More...

Company profile

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Sector 

Healthcare


AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.